Linked Life Data

11465878

Source:http://linkedlifedata.com/resource/pubmed/id/11465878

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11465878rdf:typepubmed:Citationlld:pubmed
pubmed-article:11465878lifeskim:mentionsumls-concept:C0442504lld:lifeskim
pubmed-article:11465878lifeskim:mentionsumls-concept:C0020538lld:lifeskim
pubmed-article:11465878lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:11465878lifeskim:mentionsumls-concept:C0021186lld:lifeskim
pubmed-article:11465878lifeskim:mentionsumls-concept:C0136123lld:lifeskim
pubmed-article:11465878lifeskim:mentionsumls-concept:C1273870lld:lifeskim
pubmed-article:11465878lifeskim:mentionsumls-concept:C1552617lld:lifeskim
pubmed-article:11465878lifeskim:mentionsumls-concept:C0282443lld:lifeskim
pubmed-article:11465878lifeskim:mentionsumls-concept:C0439423lld:lifeskim
pubmed-article:11465878lifeskim:mentionsumls-concept:C0439422lld:lifeskim
pubmed-article:11465878pubmed:issue8lld:pubmed
pubmed-article:11465878pubmed:dateCreated2001-7-23lld:pubmed
pubmed-article:11465878pubmed:abstractTextThe fixed low-dose combination of the ACE inhibitor perindopril and the non-thiazide diuretic indapamide has been evaluated in the management of patients with mild to moderate hypertension. Combination therapy aims to improve overall therapeutic efficacy while minimising adverse effects. In well-designed multicentre clinical trials, perindopril/indapamide at doses ranging from 2/0.625 to 8/2.5 mg/day was significantly more effective than placebo in achieving adequate blood pressure (BP) control. A similar reduction in supine BP was observed when combined perindopril/indapamide 2/0.625 mg/day was compared with losartan 50 mg/day or atenolol 50 mg/day. Similar reductions in 24-hour ambulatory BP were also seen with perindopril/indapamide 2/0.625 mg/day and irbesartan 150 mg/day. However, response and normalisation rates were significantly higher with combination therapy than with losartan or irbesartan monotherapy. Combined perindopril/indapamide 2/0.625 mg/day therapy effectively reduced BP in elderly patients aged 65 to 85 years to a significantly greater extent than either atenolol 50 mg/day or placebo. Supine BP was also normalised in approximately two-thirds of patients in a small noncomparative trial in patients with hypertension and renal impairment. Low-dose perindopril/indapamide 2/0.625 mg/day was well tolerated in clinical trials; the most common adverse events were headache and cough. Hypokalaemia, associated with the use of diuretics, occurred with a higher incidence with combined perindopril/indapamide 2/0.625 mg/day therapy than with either atenolol 50 mg/day or placebo. Perindopril/indapamide 2/0.625 mg/day has shown efficacy in well designed comparative trials with atenolol, losartan and irbesartan including elderly patients and patients with renal impairment. Studies comparing this dosage of perindopril/ indapamide with other combination therapies would be beneficial in allowing the place of perindopril/indapamide to be more accurately determined. The fixed-low dose combination of perindopril/indapamide provides a promising and well tolerated treatment option in the management of patients with mild to moderate hypertension.lld:pubmed
pubmed-article:11465878pubmed:languageenglld:pubmed
pubmed-article:11465878pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11465878pubmed:citationSubsetIMlld:pubmed
pubmed-article:11465878pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11465878pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11465878pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11465878pubmed:statusMEDLINElld:pubmed
pubmed-article:11465878pubmed:issn0012-6667lld:pubmed
pubmed-article:11465878pubmed:authorpubmed-author:GoaK LKLlld:pubmed
pubmed-article:11465878pubmed:authorpubmed-author:CheerS MSMlld:pubmed
pubmed-article:11465878pubmed:authorpubmed-author:MathesonA JAJlld:pubmed
pubmed-article:11465878pubmed:issnTypePrintlld:pubmed
pubmed-article:11465878pubmed:volume61lld:pubmed
pubmed-article:11465878pubmed:ownerNLMlld:pubmed
pubmed-article:11465878pubmed:authorsCompleteYlld:pubmed
pubmed-article:11465878pubmed:pagination1211-29lld:pubmed
pubmed-article:11465878pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:meshHeadingpubmed-meshheading:11465878...lld:pubmed
pubmed-article:11465878pubmed:year2001lld:pubmed
pubmed-article:11465878pubmed:articleTitlePerindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension.lld:pubmed
pubmed-article:11465878pubmed:affiliationAdis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nzlld:pubmed
pubmed-article:11465878pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11465878pubmed:publicationTypeReviewlld:pubmed